{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-097885","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2025-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.476878+00:00","generated_at":"2026-05-18T03:28:18.479854+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Viking Therapeutics Q2 net loss $65.6M; Phase 3 VANQUISH obesity trial underway","bullets":["Net loss $65.6M ($0.58/share) vs $22.3M ($0.20) in Q2 2024; R&D spend $60.2M vs $23.8M.","Cash and investments $808M as of June 30, 2025, down from $903M at Dec 31, 2024.","Phase 3 VANQUISH program initiated: two placebo-controlled trials (obesity and obesity+type 2 diabetes) targeting ~5,600 patients.","Phase 2 VENTURE-Oral dosing trial enrollment completed (~280 patients); top-line results expected 2H25.","Amylin agonist program progressing; IND filing planned for Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-097885","json":"https://secwatch.observer/filing/0000950170-25-097885.json","markdown":"https://secwatch.observer/filing/0000950170-25-097885.md","text":"https://secwatch.observer/filing/0000950170-25-097885.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025097885/0000950170-25-097885-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025097885/vktx-20250723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T03:28:18.479854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}